Home
Cohance Lifesciences Ltd 52 Week Low

Cohance Lifesciences Ltd
NSE: COHANCE
YEARLOW
Key Highlights
- The 52 Week Low of Cohance Lifesciences Ltd is ₹ 789.1 as of 08 Jul 25 .
Company Fundamentals for Cohance Lifesciences Ltd
Market Price of Cohance Lifesciences Ltd
1M
1Y
3Y
5Y
Last Ten Days Market Price
Date | |
---|---|
08 Jul 2025 | 990.45 |
07 Jul 2025 | 1018.75 |
04 Jul 2025 | 1043.8 |
03 Jul 2025 | 1006.65 |
02 Jul 2025 | 967.4 |
01 Jul 2025 | 960.35 |
30 Jun 2025 | 966.65 |
27 Jun 2025 | 944.05 |
26 Jun 2025 | 1002.1 |
25 Jun 2025 | 980 |
Asset Value vs Market Value of Cohance Lifesciences Ltd
Market Value
₹ 0
Asset Value
₹ 0
* All values are in ₹ crores
Historical Revenue of Cohance Lifesciences Ltd
Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services.\r\r\n\r\r\nTypes of Revenue:\r\r\n\r\r\n1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered.\r\r\n\r\r\n2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees.\r\r\n\r\r\nFormula for Revenue:\r\r\n\r\r\nThe formula for calculating revenue is based on two goods & services:\r\r\n\r\r\nFor goods:\r\r\nRevenue = Avg unit price x Number of Units sold\r\r\n\r\r\nFor services:\r\r\nRevenue = Avg unit price x Number of Customers served.
Historical Revenue of Cohance Lifesciences Ltd
Historical Net Profit of Cohance Lifesciences Ltd
Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions.\r\r\n\r\r\nNet Profit formula is expressed as:\r\r\n\r\r\nNet Profit = Total Revenue - Total Expense\r\r\n\r\r\nNet Profit Margin Ratio:\r\r\n\r\r\nNet Profit Margin Ratio = Net Profit / Total Revenue
Historical Net Profit of Cohance Lifesciences Ltd
Cohance Lifesciences Ltd News Hub
Suven Pharmaceuticals consolidated net profit declines 49.61% in the June 2024 quarter
Net profit of Suven Pharmaceuticals declined 49.61% to Rs 60.77 crore in the quarter ended June 2024
Read more
09 Aug 24
Suven Pharmaceuticals to hold board meeting
Suven Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 9 August 2024.
Read more
06 Aug 24
Suven Pharmaceuticals appoints Vivek Sharma as new Executive Chairman
Suven Pharmaceuticals announced the appointment of Vivek Sharma as the new Executive Chairman, effec
Read more
19 Sept 24
Board of Suven Pharmaceuticals approves change in Executive Chairperson
The Board of Suven Pharmaceuticals at its meeting held on 19 September 2024 has taken on record the
Read more
19 Sept 24